Announcement on the Resolution of the 10th Board of Directors of the 10th Session
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2019-008
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届10次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2019年4月15日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2019年4月26日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决的方式召开。
(四)公司现有九名董事,全体董事出席了会议,其中:八名董事亲自参加了会议,杜自弘董事委托董事长蒋晓萌先生代为出席会议并表决。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2018年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2018年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2018年度利润分配预案
董事会审议并通过了该预案。
公司2018年度拟进行现金分配,以2018年末股本344,083,828股为基数,每10股派发现金红利3.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为103,225,148.40元(含税)。2018年度不进行公积金转增股本。
表决结果:同意9票、反对0票、弃权0票。
本预案将提交股东大会审议。
详见《关于2018年度利润分配预案的公告》(临2019-015)。
4、通过了聘请公司2019年度审计机构的议案
董事会审议并通过了该议案。同意继续聘请天健会计师事务所(特殊普通合伙)为公司2019年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
该议案将提交股东大会审议。
5、通过了为控股子公司提供担保的议案
董事会审议并通过了该议案。
对控股子公司的融资及担保,设定如下额度:
|
被担保单位 |
额度(万元) |
|
浙江尖峰药业有限公司 |
30000 |
|
上海北卡医药技术有限公司及其全资子公司 |
20000 |
|
贵州黄平谷陇铭川水泥有限公司 |
30000 |
|
浙江尖峰国际贸易有限公司 |
8000 |
|
合计 |
88000 |
同意上海北卡根据实际经营情况与其下属各全资子公司共同使用上述额度。
2、尖峰国贸是大连商品交易所的指定交割仓库,根据大连商品交易所的要求,需要本公司提供保函,对所存放的期货货物提供担保。另外,为了拓展业务,尖峰国贸目前正在申请郑州商品交易所以及上海期货交易所的交割仓库资质,也需要本公司为其提供担保。为了尖峰国贸顺利开展期货交割仓库业务,拟同意为尖峰国贸出具保函,对存放在尖峰国贸的期货货物提供担保。
在设定额度内的金融机构借款及担保事宜均授权本公司董事长决定执行。
表决结果:同意9票、反对0票、弃权0票。
详见《关于为控股子公司提供担保的公告》(临2019-010)。
本议案需提交股东大会审议。
6、通过了公司会计政策变更的议案
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于公司会计政策变更的公告》(临2019-018)。
7、通过了2018年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2018年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
该报告需提交股东大会审议。
8、通过了2019年第一季度报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2019年第一季度报告详见上海证券交易所网站(www.sse.com.cn)。
9、关于公司2019年度日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意6票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘、虞建红回避了该议案的表决。
详见《关于公司2019年度日常关联交易的公告》(临2019-011)。
10、通过了授权董事长利用自有资金进行委托理财的议案
董事会审议并通过了该议案。授权董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元。每笔委托理财的期限不得超过12个月。授权期限自公司本次董事会审议通过之日起3年内有效。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
11、通过了召开2018年度股东大会的议案
董事会审议并通过了该议案。董事会决定于2019年5月24日在浙江省金华市婺江东路88号尖峰大厦召开2018年度股东大会,并提供网络表决方式。
表决结果:同意9票、反对0票、弃权0票
详见《关于召开2018年度股东大会的通知》(临2019-017)。
12、通过了公司《章程》修订案
董事会审议并通过了该修订案。
表决结果:同意9票、反对0票、弃权0票。
详见关于修订公司《章程》的公告(临2019-014)。
该议案需提交股东大会审议。
13、通过了公司新修订的《股东大会议事规则》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《股东大会议事规则》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
14、通过了公司新修订的《董事会议事规则》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《董事会议事规则》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
15、通过了尖峰药业增资的关联交易议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、刘波回避了该议案的表决。
详见《关于尖峰药业增资的关联交易公告》(临2019-013)。
16、通过了安徽众望增资和二期技改项目的议案
董事会审议并通过了该议案。
本公司控股子公司浙江尖峰药业有限公司的控股子公司上海北卡医药技术有限公司(以下简称:上海北卡)拟出资6000万元对其全资子公司安徽众望制药有限公司(以下简称:安徽众望)进行增资。增资完成后,安徽众望注册资本由原来的4000万元增加至10000万元,上海北卡仍持有100%股权。
安徽众望拟实施二期技改项目,项目总投资17500万元。具体建设内容为:生产车间三、生产车间五、生产车间六、办公楼、研发质检楼、综合仓库一、储罐区(含泵区);新增建设用地约82亩,并对现有二车间设备设施进行局部技改。
表决结果:同意9票、反对0票、弃权0票。
17、通过了2018年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
18、通过了战略规划纲要(2019-2023)
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《战略规划纲要(2019-2023)》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
19、通过了2018年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据公司《中长期激励管理办法》的规定,2018年度提取中长期激励基金3475.03万元。
表决结果:同意9票、反对0票、弃权0票。
20、通过了董事会审计委员会2018年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
21、通过了独立董事2018年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
22、通过了2018年度董事会工作报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的其他独立意见:
此外,公司独立董事对上述4(关于聘请公司2019年度审计机构的议案)、5(关于为控股子公司提供担保的议案)、6(关于公司会计政策变更的议案)、9(关于公司2019年度日常关联交易的议案)、10(关于授权董事长利用自有资金进行委托理财的议案)、15(关于尖峰药业增资的关联交易议案)、19(关于2018年度《中长期激励基金计提方案》)七项决议都发表了同意的独立意见,认为:上述董事会决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、相关附件
1、公司第十届董事会第10次会议决议
2、公司独立董事对上述相关事项的独立董事意见
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一九年四月三十日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31